Department of Neuroscience, University of Pennsylvania, Philadelphia.
Department of Psychiatry, University of Pittsburgh, Pittsburgh, Pennsylvania.
JAMA Psychiatry. 2023 Mar 1;80(3):202-210. doi: 10.1001/jamapsychiatry.2022.4599.
Abnormal sleep is frequent in psychosis; however, sleep abnormalities in different stages (ie, clinical high risk for psychosis [CHR-P], early psychosis [EP], and chronic psychosis [CP]) have not been characterized.
To identify sleep abnormalities across psychosis stages.
Web of Science and PubMed were searched between inception and June 15, 2022. Studies written in English were included.
Sleep disturbance prevalence studies and case-control studies reporting sleep quality, sleep architecture, or sleep electroencephalography oscillations in CHR-P, EP, or CP.
This systematic review and meta-analysis followed Preferred Reporting Items for Systematic Reviews and Meta-analyses (PRISMA) reporting guideline. Stage-specific and pooled random-effects meta-analyses were conducted, along with the assessment of heterogeneity, study quality, and meta-regressions (clinical stage, sex, age, medication status, and psychotic symptoms).
Sleep disturbance prevalence, self-reported sleep quality, sleep architecture (total sleep time, sleep latency, sleep efficiency, nonrapid eye movement, rapid eye movement stages, and number of arousals), and sleep electroencephalography oscillations (spindle density, amplitude, and duration, and slow wave density).
Fifty-nine studies with up to 6710 patients (n = 5135 for prevalence) and 977 controls were included. Sleep disturbance prevalence in pooled cases was 50% (95% CI, 40%-61%) and it was similar in each psychosis stage. Sleep quality was worse in pooled cases vs controls (standardized mean difference [SMD], 1.00 [95% CI, 0.70-1.30]). Sleep architecture alterations included higher sleep onset latency (SMD [95% CI]: pooled cases, 0.96 [0.62-1.30]; EP, 0.72 [0.52-0.92]; CP, 1.36 [0.66-2.05]), higher wake after sleep onset (SMD [95% CI]: pooled cases, 0.5 [0.29-0.71]; EP, 0.62 [0.34-0.89]; CP, 0.51 [0.09-0.93]), higher number of arousals (SMD [95% CI]: pooled cases, 0.45 [0.07-0.83]; CP, 0.81 [0.30-1.32]), higher stage 1 sleep (SMD [95% CI]: pooled cases, 0.23 [0.06-0.40]; EP, 0.34 [0.15-0.53]), lower sleep efficiency (SMD [95% CI]: pooled cases, -0.75 [-0.98 to -0.52]; EP, -0.90 [-1.20 to -0.60]; CP, -0.73 [-1.14 to -0.33]), and lower rapid eye movement density (SMD [95% CI]: pooled cases, 0.37 [0.14-0.60]; CP, 0.4 [0.19-0.77]). Spindle parameter deficits included density (SMD [95% CI]: pooled cases, -1.06 [-1.50 to -0.63]; EP, -0.80 [-1.22 to -0.39]; CP, -1.39 [-2.05 to -0.74]; amplitude: pooled cases, -1.08 [-1.33 to -0.82]; EP, -0.86 [-1.24 to -0.47]; CP, -1.25 [-1.58 to -0.91]; and duration: pooled cases: -1.2 [-1.69 to -0.73]; EP, -0.71 [-1.08 to -0.34]; CP, -1.74 [-2.10 to -1.38]). Individuals with CP had more frequent arousals vs CHR-P (z = 2.24, P = .02) and reduced spindle duration vs EP (z = -3.91, P < .001).
In this systematic review and meta-analysis, sleep disturbances were found to be prevalent throughout the course of psychosis, and different psychosis stages showed both shared and distinct abnormalities in sleep quality, architecture, and spindles. These findings suggest that sleep should become a core clinical target and research domain from at-risk to early and chronic stages of psychosis.
精神疾病中经常出现异常睡眠;然而,不同阶段(即精神病高危人群[CHR-P]、早期精神病[EP]和慢性精神病[CP])的睡眠异常尚未得到描述。
确定精神病各阶段的睡眠异常。
Web of Science 和 PubMed 自成立以来至 2022 年 6 月 15 日进行了搜索。纳入了以英文撰写的研究。
睡眠障碍患病率研究和病例对照研究,报告 CHR-P、EP 或 CP 中的睡眠质量、睡眠结构或睡眠脑电图振荡。
本系统评价和荟萃分析遵循系统评价和荟萃分析报告的首选报告项目(PRISMA)报告指南。进行了阶段特异性和汇总随机效应荟萃分析,并评估了异质性、研究质量和荟萃回归(临床阶段、性别、年龄、用药状况和精神病症状)。
睡眠障碍患病率、自我报告的睡眠质量、睡眠结构(总睡眠时间、睡眠潜伏期、睡眠效率、非快速眼动、快速眼动阶段和觉醒次数)和睡眠脑电图振荡(纺锤体密度、振幅和持续时间,以及慢波密度)。
纳入了 59 项研究,共纳入了多达 6710 名患者(患病率研究中 n=5135 例)和 977 名对照。汇总病例的睡眠障碍患病率为 50%(95%CI,40%-61%),在每个精神病阶段均相似。与对照组相比,病例的睡眠质量较差(标准化均数差[SMD],1.00[95%CI,0.70-1.30])。睡眠结构改变包括更长的睡眠潜伏期(SMD[95%CI]:汇总病例,0.96[0.62-1.30];EP,0.72[0.52-0.92];CP,1.36[0.66-2.05])、更高的觉醒后睡眠(SMD[95%CI]:汇总病例,0.5[0.29-0.71];EP,0.62[0.34-0.89];CP,0.51[0.09-0.93])、更多的觉醒次数(SMD[95%CI]:汇总病例,0.45[0.07-0.83];CP,0.81[0.30-1.32])、更多的第 1 阶段睡眠(SMD[95%CI]:汇总病例,0.23[0.06-0.40];EP,0.34[0.15-0.53])、更低的睡眠效率(SMD[95%CI]:汇总病例,-0.75[-0.98 至-0.52];EP,-0.90[-1.20 至-0.60];CP,-0.73[-1.14 至-0.33])和更低的快速眼动密度(SMD[95%CI]:汇总病例,0.37[0.14-0.60];CP,0.4[0.19-0.77])。纺锤体参数缺陷包括密度(SMD[95%CI]:汇总病例,-1.06[-1.50 至-0.63];EP,-0.80[-1.22 至-0.39];CP,-1.39[-2.05 至-0.74];振幅:汇总病例,-1.08[-1.33 至-0.82];EP,-0.86[-1.24 至-0.47];CP,-1.25[-1.58 至-0.91];和持续时间:汇总病例:-1.2[-1.69 至-0.73];EP,-0.71[-1.08 至-0.34];CP,-1.74[-2.10 至-1.38])。CP 患者的觉醒次数比 CHR-P 更频繁(z=2.24,P=0.02),而 CP 患者的纺锤体持续时间比 EP 更短(z=-3.91,P<0.001)。
在本系统评价和荟萃分析中,发现睡眠障碍在精神病的整个过程中普遍存在,不同的精神病阶段在睡眠质量、结构和纺锤体方面既有共同的异常,也有独特的异常。这些发现表明,睡眠应该成为精神病高危人群、早期精神病和慢性精神病各阶段的核心临床目标和研究领域。